/Content/Upload/Product/Human_ELISA_kits_Diagnocine_1200_1200(182).jpg

Human Tissue factor pathway inhibitor,TFPI ELISA Kit

Product#: CS-CSB-E08260h
$580.00
Availability:
Ships in 24 hours

The Ultimate 1-Stop ELISA Marketplace:

60,000+ ELISA kits Available to Serve Scientists from All Fields of Life Science

Always Powered by Diagnocine for Precision Research.

 
Made In-USA · ISO 13485 Certified 

Most comprehensive buffers, reagents and detection agents are provided with each kit to optimize data output.  
All-inclusive format covers everything from sample preparation to signal detection.  Every step can be customized and optimized for your precision research.
DiagnoCine Precision buffers and reagents are Made in USA ISO 13485 Certified

One Stop Purchasing but Zero Compromise on Accuracy

Why waste time searching for your ELISA kit when you can get everything in one place? Diagnocine can provide you with all the ELISA needs you have (customized ELISAs also available) on the planet through a single, streamlined ordering process.  
* all types of species
* HRP and AP detection
* Low target signal enhancement
* Inquire about a trial version or a customized version

Low Signal Optimization Reagents

4 core reagents below are included with every order, plus 1 of the 2 detection-specific reagents (matched automatically to your kit type) — 5 components, every time.

DCP-PIC100X

Protease Inhibitor Cocktail (100X)

Included with every order
 DCP-SM1AbTBS1X

SigMax 1Ab-TBS

Included with every order
 DCP-UTBS1X

Universal Blocking Buffer

Included with every order
 DCP-SM2AbTBS1X

SigMax 2Ab-TBS

Included with every order

+ the 5th component, matched to your kit's detection method:

DCP-HRPTBS1X

HRPQuench-TBS

Exclusively for HRP-based kits
OR
DCP-ALPTBS1X

ALPQuench-TBS

Exclusively for ALP-based kits

If you have any questions or need additional information, please call us at 551-245-1033 or email us at support@diagnocine.com. Our team will be happy to assist you.

Key Value Highlights

Universal Compatibility

All buffers and detection reagents work seamlessly across target proteins, bridging the gap in assay consistency.

1-Stop Convenience

Consolidate your lab's purchasing. Source all ELISA needs and experience optimal buffers and reagents in a single shipment.

Enhanced Precision

Designed by scientists for scientists,  all components are engineered to deliver sharper results and an optical signal.

Human ELISA Kit · Cardiovascular

Human Tissue factor pathway inhibitor,TFPI ELISA Kit

Sandwich quantitative immunoassay for tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) in human serum, plasma, tissue homogenates  available in multiple catalog sizes:

Trial 24T 96T

Note: Please send inquiries regarding Trial 24T orders to support@diagnocine.com.

Detection Range
0.782-50 ng/mL
Sensitivity
0.293 ng/mL
Assay Time
1-5 hours
Sample Volume
50-100 μL
Product specifications
Target nametissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)
Uniprot No.P10646
SpeciesHomo sapiens (Human)
Sample typesserum, plasma, tissue homogenates
Detection range0.782 ng/mL-50 ng/mL
Sensitivity0.293 ng/mL
Assay time1-5h
Sample loading volume50-100μL
Detection wavelength450 nm
Assay principleSandwich (Quantitative)
Data analysisStandard curve + Curve Expert software
Research areaCardiovascular
Storage condition2-8°C (see protocol for full details)
Shipping condition4 °C
Shelf life6 months
tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) serum plasma tissue homogenates Cardiovascular Human ELISA
Lead Time

10 business days

Processing + 3-5 days shipping

Availability

In Stock : USA

Worldwide shipping available

Assay principle
Sample prep
Antibody capture
450 nm detection
Standard curve
Quantification

In this sandwich ELISA, tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) in the sample is captured between a pre-coated capture antibody and a detection antibody. Signal intensity is proportional to analyte concentration. Quantification uses a standard curve fitted with Curve Expert software, covering 0.782 ng/mL-50 ng/mL with a minimum detectable dose of 0.293 ng/mL.

For research use only (RUO). Not intended for diagnostic or therapeutic purposes. Validated in human serum, plasma, tissue homogenates matrices only.
Description

This human TFPI ELISA kit employs the quantitative sandwich enzyme immunoassay technique to measure the levels of human TFPI in serum, plasma, or tissue homogenates. It also uses the enzyme-substrate chromogenic reaction to visualize and analyze the analyte levels through the color intensity. The intensity of the colored product is in direct proportion to the TFPI levels in the sample and is measured at 450 nm through a microplate reader.

TFPI is an anticoagulant protein produced primarily by the endothelium and megakaryocytes. It is the main inhibitor of the TF-dependent pathway of blood coagulation. TFPI mediates its anticoagulant activity by impeding early proteolytic events of the blood coagulation cascade, including those mediated by the TF-FVIIa catalytic complex, FXa, and early forms of the prothrombinase complex (FVa-FXa). TFPI can also enhance the effect of heparins. Studies have shown that TFPI exerts anti-angiogenic and anti-metastatic effects in vitro and in vivo. TFPI plays a significant role in the pathophysiology of many diseases, including cancer and inflammation.

Alternative Names
Anti convertin ELISA Kit; EPI ELISA Kit; Extrinsic pathway inhibitor ELISA Kit; LACI ELISA Kit; Lipoprotein associated coagulation inhibitor ELISA Kit; Lipoprotein-associated coagulation inhibitor ELISA Kit; TFI ELISA Kit; TFPI 1 ELISA Kit; TFPI ELISA Kit; TFPI1 ELISA Kit; TFPI1_HUMAN ELISA Kit; Tissue factor pathway inhibitor (lipoprotein associated coagulation inhibitor) ELISA Kit; Tissue factor pathway inhibitor ELISA Kit
Function
Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma.
Gene References into Functions
  1. A significant degradation of TFPI was induced by ROS exposure, resulting in a decreased ability to bind FXa. ROS induce a procoagulant state in endothelial cells by altering TFPI structure, resulting in inhibition of TFPI binding to Factor Xa PMID: 25712553
  2. TNFalpha and Stx-1 compared to TNFalpha alone leads to an increase in procoagulant TF on endothelial cells, which is explained by a significant decrease in TFPI not co-localized with TF and not to an increase in TF not co-localized with TFPI PMID: 25864889
  3. rs5940 and rs7586970 moderate TFPI plasma levels and are candidate risk factors for thrombosis, but the regulation of TFPI plasma levels involves genetic factors beyond the TFPI gene. Review. PMID: 25879386
  4. This study indicates that genetic and phenotypic variation of both TFPIalpha and TFPIbeta, more than TF, are markers of cancer progression. PMID: 25882602
  5. coagulation system, TFPI play an important role in the pathogenesis of CRSwNP. PMID: 26163243
  6. Association between genetic polymorphisms and deep vein thrombosis in a Chinese population. PMID: 26233570
  7. the main finding of the current study is the remarkable elevation in the plasma levels of both total and free TFPI in septic patients at baseline. The levels of both forms of the inhibitor remained elevated throughout the first 24 h with further elevation after enoxaparin administration. PMID: 26377606
  8. Tissue factor pathway inhibitor-2 gene polymorphisms were associated with coronary atherosclerosis in the Chinese population PMID: 26496276
  9. HIF-1alpha is involved in the transcriptional regulation of the TFPI gene, and suggests that a hypoxic microenvironment inside a breast tumor may induce a procoagulant state in breast cancer patients. PMID: 26598923
  10. Tissue factor pathway inhibitor activity and APC resistance are related to coronary heart disease risk in women, but may not explain the increased CHD risk due to estrogen plus progestin therapy. PMID: 26681757
  11. Circulating FVII, FVIIa and TFPI were significantly elevated in women with severe preeclampsia in the absence of comparable changes in plasma TF levels. PMID: 26765308
  12. a concentration of tissue factor pathway inhibitor was significantly lower in patients with essential thrombocythemia with JAK2 V617F mutation as compared with patients without the mutation PMID: 26945263
  13. Tissue Factor Pathway Inhibitor Gene Polymorphism is associated with response to therapy in Colorectal Cancer. PMID: 26968713
  14. miR-27a/b and miR-494 regulate TFPIalpha expression; there may be a role of these miRNAs in the estrogen-mediated downregulation of TFPIalpha PMID: 26999003
  15. ERalpha can interact with all three ERE half-sites in the TFPI 5'-flanking region. PMID: 26999742
  16. This review presents a comprehensive understanding of TFPI structure, biochemistry, and cellular expression which is necessary to understand how it modulates bleeding in hemophilia and the physiological impact of therapeutic agents targeting TFPI. PMID: 27207418
  17. Cleavage of FV at Arg(1545) , which abolishes the anticoagulant properties of FV and commits FV to the procoagulant pathway, is inhibited by binding of the TFPIalpha C-terminus to the FV acidic region PMID: 27801970
  18. Developed functional protein S assays that measure both the activated protein C- and TFPI-cofactor activities of protein S in plasma, which are hardly if at all affected by the FV Leiden mutation. PMID: 28211163
  19. TFPI-1 was a valuable predictor of deep venous thrombosis and tumor metastasis in non-small cell lung cancer patients. PMID: 28246607
  20. Among high-risk women, the tissue factor pathway inhibitor activity of patients with gestational vascular complications is higher than that in other patients. Hence, these markers could augment a screening strategy. PMID: 28328938
  21. Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1). PMID: 28393401
  22. TFPI single nucleotide polymorphism is associated with venous thromboembolism. PMID: 28421636
  23. These data indicate that both isoforms of TFPI are present in advanced plaques and that anti-inflammatory M2 macrophages may be a potential source of TFPI. PMID: 28482260
  24. plasma level not different between pre-eclampsia and normal pregnancy PMID: 28521572
  25. Patients with early onset preeclampsia are characterised by an attenuated coagulation response characterised by reduced thrombin generation stimulated by low-dose TF and elevated plasma TFPI activity. PMID: 28569919
  26. The results show that cholesterol crystals induce TFPI and cytokine expression in M2-polarized macrophages through activation of the endoplasmic reticulum stress pathway and that TFPI has a protective effect against TNF-alpha and IL-6 mediated inflammation. PMID: 28712870
  27. Genetic variations of the TFPI genes seem to be related with coronary artery disease, which likely cooperate with metabolic risk factor (diabetes mellitus) and play critical roles in the pathogenesis of coronary artery disease in Han Chinese. PMID: 28716011
  28. The aim of this study was to evaluate the concentration of TF and its inhibitor TFPI in blood plasma, the impact of traditional and non-traditional cardiovascular risk factors on their concentration and the impact of both markers of haemostasis on the severity of subclinical atherosclerosis. PMID: 28749986
  29. For the first time, we show that a TFPI variant is significantly associated with fibrinogen levels and risk of coronary artery disease. PMID: 28894953
++ 21 more research findings link this target to additional biology. Showing the 29 most recent — the full set appears on the complete datasheet.
Tissue Specificity
Mostly in endothelial cells.
Subcellular Location
[Isoform Alpha]: Secreted.; [Isoform Beta]: Microsome membrane; Lipid-anchor, GPI-anchor.
Database Links

HGNC: 11760

OMIM: 152310

KEGG: hsa:7035

STRING: 9606.ENSP00000233156

UniGene: Hs.516578

Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
Human Tissue factor pathway inhibitor,TFPI ELISA Kit
ng/mlOD1OD2AverageCorrected
502.519 2.623 2.571 2.440
252.021 2.154 2.088 1.957
12.51.434 1.456 1.445 1.314
6.250.813 0.838 0.826 0.695
3.1250.436 0.445 0.441 0.310
1.5630.304 0.310 0.307 0.176
0.7820.221 0.216 0.219 0.088
00.130 0.131 0.131
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human TFPI in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:1Average %93
Range %88-97
1:2Average %101
Range %97-105
1:4Average %94
Range %89-98
1:8Average %96
Range %91-102
Recovery
The recovery of human TFPI spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9489-98
EDTA plasma (n=4)8681-92

Satisfaction
Quality Rating
Value Rating
Style Rating
X